These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Treatment of chronic hepatitis C with recombinant interferon alfa-2b for nine months.
    Author: Pérez R, Pravia R, Linares A, González M, Rodríguez M, Lombraña JL, Riestra S, Suárez A, Rodrigo L.
    Journal: Gut; 1993; 34(2 Suppl):S136-8. PubMed ID: 8314481.
    Abstract:
    This randomised, controlled trial was designed to assess the response to a nine month course of interferon (IFN) alfa-2b, starting with a higher than usual dose. Forty eight patients received IFN 5 million units (MU) three times a week for eight weeks followed by 3 MU three times weekly for seven months; 25 patients in the control group received no treatment. The overall response to treatment was 68.7%, an improvement over other studies, but the high rate of relapse (85% in patients who responded) suggested that a nine month treatment period was insufficient in most cases. Histological improvement was seen in more than 80% of responders to interferon, including a reduction in inflammatory activity, necrosis, and fibrosis.
    [Abstract] [Full Text] [Related] [New Search]